Application of pulmonary surfactant in the treatment of severe acute respiratory distress syndrome in different age baby with congenital heart diseases_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

ZHANG Rongyuan ,  WANG Xu , LI Shoujun , YAN Jun , YANG Juxian

Pediatric Cardiac Surgery Center, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences, Peking Union Medical College, State Key Laboratory of Cardiovascular Disease, Beijing, 100037, P.R.China;

Corresponding author：

WANG Xu, Email: fwpicu@163.com

Keywords：

Pulmonary surfactant; congenital heart disease; acute respiratory distress syndrome; age

DOI：

10.7507/1007-4848.201801050

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To evaluate the efficacy of pulmonary surfactant (PS) on severe acute respiratory distress syndrome (ARDS) in different age baby with congenital heart disease. Methods We divided 43 baby patients into two separate groups including a little baby group (12 patients with age less than 3 months) and an infants group (31 patients with age of 3 months to one year). Both groups of patients were treated with intratracheal PS at the same time. The clinical data were collected and analyzed. Results The little baby group had lower body weight. There was no statistical difference in the cardiopulmonary bypass (CPB) time, operation blocking time, mechanical ventilation time, ICU stay time between the two groups (P>0.05). Before treatment, arterial partial presurre of oxygen (PaO₂), fractional oxygen concentration in inspire gas (FiO₂), the ratio of arterial PO₂ to the inspired oxygen fraction (P/F) and arterial-alveolar N₂ difference or gradient (a/A) had no difference between the two groups (P>0.05). After treatment, PaO₂ and P/F of both groups were significantly lower than before (P<0.05), and FiO₂ and P/F were significantly higher than before (P<0.05). After 24 h of treatment, PaO₂ and P/F of the little baby group was significantly higher than that of the infants group (P<0.05), and FiO₂ and P/F were significantly lower than those of the infants group (P<0.05). Conclusion PS treating severe ARDS in little baby with congenital heart disease has better effect than infants.

Citation： ZHANG Rongyuan, WANG Xu, LI Shoujun, YAN Jun, YANG Juxian. Application of pulmonary surfactant in the treatment of severe acute respiratory distress syndrome in different age baby with congenital heart diseases. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2018, 25(11): 977-980. doi: 10.7507/1007-4848.201801050 Copy

1.	龚书榕, 张颖蕊, 于荣国. 小儿重症及复杂先天性心脏病术后急性呼吸窘迫综合征的危险因素分析. 南方医科大学学报, 2016, 36(12): 1660-1666.
2.	Hidalgo A, Cruz A, Pérez-Gil J. Pulmonary surfactant and nanocarriers: Toxicity versus combined nanomedical applications. Biochim Biophys Acta, 2017, 1859(9 Pt B): 1740-1748.
3.	Alten JA, Borasino S, Pearce FB, et al. Surfactant treatment for congenital heart disease patients with acute respiratory distress syndrome. Congenit Heart Dis, 2010, 5(6): 624-628.
4.	Wong JJ, Jit M, Sultana R, et al. Mortality in pediatric acute respiratory distress syndrome: A systematic review and meta-snalysis. J Intensive Care Med, 2017, [Epub ahead of print].
5.	Echaide M, Autilio C, Arroyo R, et al. Restoring pulmonary surfactant membranes and films at the respiratory surface. Biochim Biophys Acta, 2017, 1859(9 Pt B): 1725-1739.
6.	Amigoni A, Pettenazzo A, Stritoni V, et al. Surfactants in acute respiratory distress syndrome in infants and children: past, present and future. Clin Drug Investig, 2017, 37(8): 729-736.
7.	Sahetya SK, Mancebo J, Brower RG. Fifty years of research in ARDS. Vt selection in acute respiratory distress syndrome. Am J Respir Crit Care Med, 2017, 196(12): 1519-1525.
8.	Heidemann SM, Nair A, Bulut Y, et al. Pathophysiology and management of acute respiratory distress syndrome in children. Pediatr Clin North Am, 2017, 64(5): 1017-1037.
9.	Lim JK, Lee JH, Cheifetz IM. Special considerations for the management of pediatric acute respiratory distress syndrome. Expert Rev Respir Med, 2016, 10(10): 1133-1145.
10.	Filoche M, Tai CF, Grotberg JB. Three-dimensional model of surfactant replacement therapy. Proc Natl Acad Sci U S A, 2015, 112(30): 9287-9292.
11.	Gill SE, Yamashita CM, Veldhuizen RA. Lung remodeling associated with recovery from acute lung injury. Cell Tissue Res, 2017, 367(3): 495-509.
12.	Han S, Mallampalli RK. The role of surfactant in lung disease and host defense against pulmonary infections. Ann Am Thorac Soc, 2015, 12(5): 765-774.
13.	Willson DF1, Thomas NJ, Markovitz BP, et al. Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial. JAMA, 2005, 293(4): 470-476.
14.	Spragg RG, Lewis JF, Walmrath HD, et al. Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl J Med, 2004, 351(9): 884-892.

1. 龚书榕, 张颖蕊, 于荣国. 小儿重症及复杂先天性心脏病术后急性呼吸窘迫综合征的危险因素分析. 南方医科大学学报, 2016, 36(12): 1660-1666.
2. Hidalgo A, Cruz A, Pérez-Gil J. Pulmonary surfactant and nanocarriers: Toxicity versus combined nanomedical applications. Biochim Biophys Acta, 2017, 1859(9 Pt B): 1740-1748.
3. Alten JA, Borasino S, Pearce FB, et al. Surfactant treatment for congenital heart disease patients with acute respiratory distress syndrome. Congenit Heart Dis, 2010, 5(6): 624-628.
4. Wong JJ, Jit M, Sultana R, et al. Mortality in pediatric acute respiratory distress syndrome: A systematic review and meta-snalysis. J Intensive Care Med, 2017, [Epub ahead of print].
5. Echaide M, Autilio C, Arroyo R, et al. Restoring pulmonary surfactant membranes and films at the respiratory surface. Biochim Biophys Acta, 2017, 1859(9 Pt B): 1725-1739.
6. Amigoni A, Pettenazzo A, Stritoni V, et al. Surfactants in acute respiratory distress syndrome in infants and children: past, present and future. Clin Drug Investig, 2017, 37(8): 729-736.
7. Sahetya SK, Mancebo J, Brower RG. Fifty years of research in ARDS. Vt selection in acute respiratory distress syndrome. Am J Respir Crit Care Med, 2017, 196(12): 1519-1525.
8. Heidemann SM, Nair A, Bulut Y, et al. Pathophysiology and management of acute respiratory distress syndrome in children. Pediatr Clin North Am, 2017, 64(5): 1017-1037.
9. Lim JK, Lee JH, Cheifetz IM. Special considerations for the management of pediatric acute respiratory distress syndrome. Expert Rev Respir Med, 2016, 10(10): 1133-1145.
10. Filoche M, Tai CF, Grotberg JB. Three-dimensional model of surfactant replacement therapy. Proc Natl Acad Sci U S A, 2015, 112(30): 9287-9292.
11. Gill SE, Yamashita CM, Veldhuizen RA. Lung remodeling associated with recovery from acute lung injury. Cell Tissue Res, 2017, 367(3): 495-509.
12. Han S, Mallampalli RK. The role of surfactant in lung disease and host defense against pulmonary infections. Ann Am Thorac Soc, 2015, 12(5): 765-774.
13. Willson DF1, Thomas NJ, Markovitz BP, et al. Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial. JAMA, 2005, 293(4): 470-476.
14. Spragg RG, Lewis JF, Walmrath HD, et al. Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl J Med, 2004, 351(9): 884-892.

Previous Article
Early outcomes of 203 neonates with low birth weight undergoing cardiac surgery and analysis of death causes
Next Article
Integral classification method of thoracic deformity

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Application of pulmonary surfactant in the treatment of severe acute respiratory distress syndrome in different age baby with congenital heart diseases

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content